Enriched Signalling Pathways in Venetoclax-Relapsed Chronic Lymphocytic Leukemia (CLL) Cells and Targeting Using a Protac-Based Bcl-2/Bcl-Xl DegraderDaisy Diaz Rohena, Deepa Sampath, Arnau Peris Cuesta et al.|Blood|2023Cited by 1
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic LeukemiaBritten Gordon, Jennifer A. Woyach, Arnau Peris et al.|Blood Cancer Discovery|2025Cited by 1